The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.
 
Lana Khalil
No Relationships to Disclose
 
Sandra Kang
No Relationships to Disclose
 
Ashley McCook-Veal
No Relationships to Disclose
 
Amber Draper
No Relationships to Disclose
 
Maria Diab
No Relationships to Disclose
 
Walid Labib Shaib
Honoraria - Blueprint Medicines; BMS; Ipsen; Lexicon; Mylan; Natera
Research Funding - ArQule (Inst); Basilea (Inst); GlaxoSmithKline (Inst); Lexicon (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Lexicon
 
Olatunji B. Alese
Consulting or Advisory Role - Pathema GX; Pfizer; QED Therapeutics; Taiho Oncology
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corcept Therapeutics (Inst); Hutchison MediPharma (Inst); Ipsen (Inst); MabSpace Biosciences (Inst); PCI Biotech (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
 
Bassel F. El-Rayes
Honoraria - Charles River Associates
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Exelixis; Genentech; QED Therapeutics; QED Therapeutics; Seagen; Stemline Therapeutics; Taiho Oncology; Taiho Oncology
Speakers' Bureau - Intellisphere
Research Funding - Adaptimmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); ICON Clinical Research (Inst); IQvia (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Wayne State University (Inst); Xencor (Inst); Zymeworks (Inst)
Other Relationship - ERYTECH Pharma; Exelixis; SC Liver Research Consortium
 
Mehmet Akce
Consulting or Advisory Role - AstraZeneca; Curio Science; Eisai; Exelixis; GlaxoSmithKline; Ipsen; Isofol Medical; QED Therapeutics
Research Funding - Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); IMPAC Medical Systems (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); RedHill Biopharma (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); Xencor (Inst)